Caribou Biosciences Inc. (CRBU)
0.79
-0.07 (-8.25%)
At close: Apr 03, 2025, 3:59 PM
0.79
-0.01%
After-hours: Apr 03, 2025, 04:05 PM EDT
-8.25% (1D)
| Bid | 0.78 |
| Market Cap | 73.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.65 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | -0.67 |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 883,010 |
| Avg. Volume (20D) | 1,243,591 |
| Open | 0.82 |
| Previous Close | 0.86 |
| Day's Range | 0.78 - 0.85 |
| 52-Week Range | 0.72 - 4.85 |
| Beta | 2.34 |
About CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 23, 2021
Employees 147
Stock Exchange NASDAQ
Ticker Symbol CRBU
Website https://cariboubio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CRBU stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 1301.10% from the latest price.
Stock ForecastsNext Earnings Release
Caribou Biosciences Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-25.35%
Caribou Biosciences shares are trading lower after...
Unlock content with
Pro Subscription
